Triple combination therapy with hydroxychloroquine, sulfasalazine, and methotrexate (MTX) has been shown in double-blind, placebo-controlled studies to be significantly superior to MTX alone (Paulus 50% responses of 77% versus 33%). In long-term follow-up studies, this therapy has now been shown to be well-tolerated with continued efficacy in the majority of patients.
|Original language||English (US)|
|Journal||Clinical and experimental rheumatology|
|Issue number||6 SUPPL. 18|
|Publication status||Published - Nov 8 1999|
- Rheumatoid arthritis
ASJC Scopus subject areas
- Immunology and Allergy